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Abstract
Background: Human Immunodeficiency Virus (HIV) infection is a dynamic interaction of the
pathogen and the host uniquely defined by the preference of the pathogen for a major component
of the immune defense of the host. Simple mathematical models of these interactions show that
one of the possible outcomes is a chronic infection and much of the modelling work has focused
on this state.
Bifurcation: However, the models also predict the existence of a virus-free equilibrium. Which
one of the equilibrium states the system selects depends on its parameters. One of these is the net
extinction rate of the preferred HIV target, the CD4+ lymphocyte. The theory predicts, somewhat
counterintuitively, that above a critical extinction rate, the host could eliminate the virus. The
question then is how to increase the extinction rate of lymphocytes over a period of several weeks
to several months without affecting other parameters of the system.
Testing the hypothesis: Proposed here is the use of drainage, or filtration, of the thoracic duct
lymph, a well-established surgical technique developed as an alternative for drug
immunosuppression for organ transplantation. The performance of clinically tested thoracic duct
lymphocyte depletion schemes matches theoretically predicted requirements for HIV elimination.
Dynamics of HIV infection and selection of 
equilibrium states
Reports on the high turnover rates of HIV and its preferred
target, CD4+ lymphocytes, during the latent phase of HIV
infection [1-3] have established the virus as a prime sus-
pect for direct demolition of the immune system. These
clinical findings have also stimulated further efforts at
modeling [4,5], and quantitative experimental observa-
tion [6]. Major journals have a preference for experimen-
tal or clinical data, and the results of mathematical
modelling have not reached the broader AIDS research
community. For example, the most interesting result of a
simple dynamic model published several years ago [7],
namely the existence of multiple equilibrium states, one
of which is virus-free, has not been discussed in any of the
recent publications on HIV response to anti-viral drugs.
For a general medical audience it would be desirable to
describe the basic features of the dynamics of HIV infec-
tion without recourse to any mathematical formulations.
Dynamics implies change over time and the behavior of a
dynamic system is defined by stating how the system var-
iables affect each other during a unit of time. In the sim-
plest model there are three system variables: (i) the
number of uninfected lymphocytes, (ii) the number of
infected lymphocytes and (iii) the number of free virions.
The system equations describe how these populations
interact. For HIV/CD4+, some of these interactions are
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understood and generally accepted; others are more spec-
ulative, and are subject to further study. However, even
with different assumptions about these lesser known
aspects, the most interesting result is little affected because
it derives from the fact that the rate of infection, i.e. the
number of newly infected cells in a unit of time, is propor-
tional to the product of the number of uninfected cells and
the number of free virions. This makes the resulting equa-
tions non-linear, and when the question of equilibrium is
addressed, which is done by setting all rates (changes with
time) equal to zero, there are two distinct solutions. One
of these is free of virus, i.e. the number of virions (and
infected cells) is equal to zero, whilst the other equilib-
rium state has non-zero values for all three populations
and thus corresponds to a chronic infection. Which one of
the two equilibrium states the system attains depends on
the values of the system parameters. The most natural
parameter to consider for switching the states is the differ-
ence between the rates at which uninfected cells are dying
and proliferating. If this parameter, the net extinction rate
of healthy lymphocytes, is increased above a critical value,
the virus-free equilibrium is selected. This selection (bifur-
cation) is driven by the conditions of stability; the chronic
infection state becomes unstable, i.e. any disturbance
takes the system out of it, whilst the virus-free state
becomes stable. Once the net extinction rate exceeds the
critical value, the system finds its way out of infection. It
just so happens that the amount by which the extinction
rate needs to be changed, and this based on our current
best estimates of other values, is quite modest – several
percent of the total lymphocyte population needs to be
removed daily.
Depletion of lymphocytes as a therapy for AIDS, based on
a population dynamic model, has been advocated by de
Boer and Boucher [8]. They proposed that using a suitable
immunosuppressant or CD4-killing drug in combination
with an anti-viral therapy may eliminate the infection.
This author has arrived at the same result independently
using a population dynamics model (three populations,
as described above), but also using an expanded model
that includes the immune response and, in particular, Tat
protein-induced apoptosis [9]. The intervention by lym-
phocyte depletion will work as predicted by modelling
only if other parameters of the system remain substan-
tially unaffected. This is an unlikely outcome with immu-
nosuppressive drugs. Results from limited attempts to use
them in HIV-positive patients [10-12] are interesting, but
not very encouraging. In fact, the observed rise in CD4+
counts runs contrary to the expected effect of depletion.
Activation of latent CD4+ by OKT3 and IL-2 with inten-
tion to purge the virus has also been attempted [13], but
the outcome was a surprisingly prolonged depletion of
CD4+ with little effect on the virus. Our knowledge of the
immune system interactions seems inadequate to provide
satisfactory explanations for such a response.
As a further illustration of how complex different inter-
ventions with biological modifiers can be, treatments
with depleting CD4 monoclonal antibody showed a pref-
erential loss of naive T cells, but did not affect IFN-gamma
secreting cells [14], providing a clue as to why such deple-
tions did not meet expectations in treating autoimmune
diseases.
Depletion of lymphocytes from the lymphatic 
circulation
The prediction of the theoretical model calls for the
removal of 5 to 10 percent of the total lymphocyte pool
per day. The critical value is subject to uncertain estimates
of some parameters, and it does differ between the simple,
three-parameter and the five-parameter, expanded model.
Perhaps the best approach would be to begin depletion,
monitor the response by the viral RNA, and then adjust
the depletion rate. All of this suggests that some means of
physical removal would be best suited. Extracorporeal
blood cell separation is a possibility, but the estimate of
several hours that the patient would have to spend on the
machine daily for several weeks to months, is very dis-
couraging. However, filtration of the thoracic duct lymph,
where lymphocytes are present in high concentration,
seems almost ideal. The technique of duct drainage for
lymphocyte depletion was developed in the sixties and
the seventies in order to reduce the risk of organ rejection
[15-21]. It has found fairly broad acceptance in renal
transplantation [22-25] where the patients would typi-
cally be treated for four weeks prior to receiving a trans-
plant. With improved techniques of tissue matching and
better immunosuppressive drugs, the thoracic duct drain-
age lost its appeal in transplant surgery, but it remains an
interesting approach to treatments of autoimmune condi-
tions such as rheumatoid arthritis (RA) [26-28]. Improve-
ments in the biocompatibilty of implants could
ostensibly even extend the impressive performance of
access devices that have remained potent for hundreds of
days [29]. The number of lymphocytes removed from RA
patients by thoracic duct filtration [29] is in the range of
modelling predictions for elimination of the virus (on the
order of ten billion per day at the start of the treatment).
An alternative to removal of lymphocytes by duct drain-
age or filtration is their diversion from the lymphatic sys-
tem into the gastro-intestinal tract, which has been
demonstrated in experimental animals [30-32]. Cells are
killed while the precious protein is recycled, avoiding the
problem of protein loss by drainage. There is no evidence
that HIV could survive gastric passage. The drawback of
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the number of lymphocytes removed. This may not be
such a serious limitation, provided the critical value is
exceeded. The rate of lymphocyte removal then simply
determines the duration of the treatment and the reduc-
tion in the number of lymphocytes the patient will expe-
rience. This, of course, is an issue that needs careful
consideration. Depletion of lymphocytes will cause a
transient reduction of their pool (with counts predicted to
drop to a few hundred CD4 lymphocytes/microliter), and
thus affect the general immune competence. The interven-
tion by depletion should be done as early as possible
when the rates of removal necessary are lower and the
total pool is less reduced.
Concluding remarks
Unfortunately, theoretical predictions of system dynamics
are not very encouraging for the prospects of HIV vaccines.
In principle, the vaccination primes the system for a faster,
stronger response, including proliferation of the respond-
ing lymphocytes. As the same cells are targets for the virus,
the system moves away from the stability condition for
the virus-free equilibrium. Apoptosis of uninfected CD4+
lymphocytes in HIV infection is an appropriate response
(for the host), albeit insufficient, since the cause of apop-
tosis is Tat protein produced by only the infected cells
themselves. This prevents the system from eliminating the
virus because the apoptotic signal weakens along with the
infection. This suggests a possibility for a pharmacological
intervention based on Tat protein that could sustain the
apoptotic signal without introducing molecular modifiers
with potentially broader effects. If vaccinations were to
work, upon entry of the pathogen, they should provoke
apoptosis of lymphocytes, not their proliferation.
Until such discoveries are made, and to test perhaps their
ultimate potential, a simple surgical intervention to allow
for removal of lymphocytes merits further investigation.
Dangers posed to the patient would be significant, both
due to morbidity of the procedure itself, and the expected,
but difficult to precisely predict cumulative effects on
immunocompetence. An attractive aspect of using physi-
cal means of depletion is the possibility to terminate the
treatment instantly and completely, as soon as any major
deviations from the expected response would arise, indi-
cating a failure of the model and alarming for unexpected
risks.
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